Dr. Eichenbaum will discuss the bioresorbable, hydrogel axitinib intravitreal implant that is under investigation in the SOL-1 phase 3 trial for the treatment of neovascular age-related macular degeneration.
This activity is supported by an independent medical education grant from Ocular Therapeutix.